The Prostate Cancer Foundation Scientific Retreat 2025 (PCF 2025)

Investigational All-in-One CAR T-Cell Platform for Prostate Cancer - Nour Shobaki

Investigational Therapies Target STEAP1 and DLL3 in Advanced Prostate Cancer - Rahul Aggarwal

GTB-5550: A Tri-specific NK Cell Engager Designed to Target B7-H3 - Nicholas Zorko

Multidisciplinary Care, Early Detection, and Ongoing Prostate Cancer Challenges - Maha Hussain

A Global Investigation into the Drivers of Cancer Care Disparities - Edward Christopher Dee

PRESTO Trial Final Results for High-Risk Biochemically Recurrent Prostate Cancer - Rahul Aggarwal

Preclinical Study Evaluates p300 Protein in AR-Driven Prostate Cancer - Jie Luo

AI Applications in Prostate Cancer Pathology and Prognostics - Tamara Lotan

The Role of the Gut Microbiome in Prostate Cancer - Karen Sfanos

Moving Beyond DNA: The Role of Early, Multi-Modal Genomic Testing in Prostate Cancer Management - Colin Pritchard

Addressing Urology Disparities Through Community Partnerships and Institutional Collaboration - Samuel Washington

Exploring STEAP1 in Prostate Cancer: From CRISPR Screens to a Neoadjuvant Bispecific Trial - Carissa Chu

Precision Medicine in Advanced Prostate Cancer: Key Advances and What’s Next - Emmanuel Antonarakis

Phase 1B Trial Combines Xaluritamig with Hormone Therapy for Metastatic Prostate Cancer - Nicholas Zorko

Optimizing Advanced Prostate Cancer Care: Balancing Intensification and Overtreatment - Gerhardt Attard

Targeting NSD2 to Reverse Treatment Resistance in Advanced Prostate Cancer - Jia Li

Implementing Lutetium-PSMA — From Trial Design to Operations - Oliver Sartor

Safety and Dosing of Lutetium-PSMA in the Pre-Chemotherapy PSMAfore Trial - Oliver Sartor

Real-World Analysis of Genetic Testing Rates and Barriers in Metastatic Prostate Cancer - Pedro Barata

Interim PSMAddition Analysis Shows Lutetium PSMA-617 Improves rPFS in mHSPC - Scott Tagawa

Genomic Testing in Prostate Cancer: Management, Applications, and Treatment Selection - Joaquin Mateo

Analysis of the Phase III CAPItello-281 Trial: Capivasertib plus Abiraterone in PTEN-Deficient mHSPC - Daniel George

Integrating PSMA PET Imaging: From Interpretation to Systemic Therapy Selection in Castration-Resistant Prostate Cancer - Oliver Sartor

ctDNA as an Early Response Signal in RLT and mCRPC Care - Alexander Wyatt

CAPItello-281: Targeting the AKT Pathway in PTEN-Deficient mHSPC Presentation - Daniel George